Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. [electronic resource]
Producer: 19991020Description: 296-304 p. digitalISSN:- 0364-5134
- Adult
- Alemtuzumab
- Antibodies, Monoclonal -- therapeutic use
- Antibodies, Monoclonal, Humanized
- Antibodies, Neoplasm -- therapeutic use
- Enzyme-Linked Immunosorbent Assay
- Humans
- Inflammation -- pathology
- Magnetic Resonance Imaging
- Multiple Sclerosis -- pathology
- Time Factors
- Tumor Necrosis Factor-alpha -- analysis
No physical items for this record
Publication Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.